1. Combinaton or Individual Lipid-Lowering Therapy-What Is The Right Direction?
- Author
-
Pavol Jarcuska, B. Novakova, Dominik Pella, L. Jedlickova, Jan Fedacko, L. Jackova, L. Merkovska, and Martin Janicko
- Subjects
medicine.medical_specialty ,Atherogenic dyslipidemia ,Heart disease ,business.industry ,nutritional and metabolic diseases ,Pharmacology ,medicine.disease ,Lipid-lowering therapy ,medicine ,lipids (amino acids, peptides, and proteins) ,In patient ,Risk factor ,Metabolic syndrome ,Intensive care medicine ,business ,Dyslipidemia ,Cause of death - Abstract
Dyslipidemia is one of the most important risk factor for cardiovascular diseases, which are the main cause of death worldwide. There are two treatment options for dyslipidemia that complement each other. Despite the spread of lipid-lowering therapy and its increasing use in clinical practice, a large numbers of patients still remain in high “residual cardiovascular risk.” Currently at the forefront of lipid-lowering agents, statins significantly lower LDLcholesterol but in the terms of effect on the levels of triglycerides and HDL-cholesterol there is much less impact. This is a serious problem, especially in patients with atherogenic dyslipidemia, typical for patients with metabolic syndrome. For this reason, high attention has recently been given to combination of lipid-lowering agents. It is also important to mention the important pleiotropic effects of hypolipidemics. This article provides an overview of current lipid-lowering agents, their comparisons as well as new recommendations in the management of dyslipidemia.
- Published
- 2014